Julie Hambleton
Director/Board Member presso IGM BIOSCIENCES, INC.
Patrimonio netto: 260 435 $ in data 31/03/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Fred Schwarzer | M | 72 | 21 anni | |
Daniel Lynch | M | 65 | 8 anni | |
Michael Varney | M | 65 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 19 anni |
Akshay Nanduri | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
Jonathan Lim | M | 52 | 6 anni | |
Saqib Islam | M | 54 | 7 anni | |
Robert Shoemaker | M | 43 | 6 anni | |
Michael Lee | M | 45 | 5 anni | |
Thomas Hawes | M | 48 |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
Jean Liu | F | 55 | 2 anni | |
T. S. Harigopal | M | - | 3 anni | |
Jakob Haldor Topsøe | M | 55 | 6 anni | |
Felix Baker | M | 55 | 3 anni | |
Christina Teng Topsøe | F | 43 | 6 anni | |
Pratik Multani | M | 57 | 6 anni | |
William Strohl | M | 71 | 6 anni | |
Badreddin Edris | M | 37 | 6 anni | |
Valerie Start | M | 64 | 5 anni | |
Scott Morrison | M | 66 | 6 anni | |
Christopher M. Duke | M | 52 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 anni |
David Chacko | M | 41 | 5 anni | |
Kim Diamond | F | - | 6 anni | |
Chandra D. Lovejoy | F | 52 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 3 anni |
Jason Throne | M | 53 | 5 anni | |
Paul A. Barsanti | M | - | 5 anni | |
James Bristol | M | 77 | 6 anni | |
Alan Fuhrman | M | 67 | 5 anni | |
Herschel Weinstein | M | 68 | 4 anni | |
Freda Lewis-Hall | M | 69 | 7 anni | |
Carlos Alban | M | 61 | 2 anni | |
M. Wilsey | M | 71 | 5 anni | |
Theodore Samuels | M | 69 | 7 anni | |
Alexander Casdin | M | 56 | 6 anni | |
Wendy Yarno | F | 68 | 5 anni | |
Ebun Garner | M | 52 | 3 anni | |
James Cassidy | M | 65 | 7 anni | |
Les Brail | M | - | - | |
Suraj Mudichintala | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
Brain Baker | M | - | - | |
Mindy Goldman | F | - |
The University of California, San Francisco
| 31 anni |
Nik Chetwyn | M | - | 3 anni | |
Angus M. Sinclair | M | - | 6 anni | |
Shannon Morris | M | 54 | 2 anni | |
Alison Milhous | F | 45 | - | |
Rachel Cervantes | F | - | - | |
Tai-An Lin | M | 61 | 1 anni | |
Daniel Pichl | M | 41 | 4 anni | |
Juan-Pablo Mas | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | 2 anni |
Emir Sandhu | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | 4 anni |
Michael Nofi | M | 53 | 5 anni | |
Matthew Jacobson | M | - |
The University of California, San Francisco
| 22 anni |
Fady Malik | M | 59 |
The University of California, San Francisco
| 24 anni |
Mark Smith | M | 72 |
The University of California, San Francisco
| 30 anni |
David A. Kessler | M | 72 |
The University of California, San Francisco
| 21 anni |
Ronald A. Krasnow | M | 61 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 4 anni |
Bruce Keyt | M | 71 | 14 anni | |
Pamela Palmer | M | 61 |
The University of California, San Francisco
| 28 anni |
Craig David Gordon | M | - |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | - |
Jonathan Fleming | M | 66 |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
Frank Perier | M | 64 | 5 anni | |
Kristen Hege | M | 60 |
The University of California, San Francisco
| 28 anni |
David Diaz-Casariego | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Stephen P. Squinto | M | 67 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 6 anni |
Lamberto Andreotti | M | 73 | 19 anni | |
William Ringo | M | 78 | 7 anni | |
Pascal Soriot | M | 63 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
Ian Clark | M | 62 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 13 anni |
Sheila Gujrathi | M | 53 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 11 anni |
Louis Lavigne | M | 75 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 23 anni |
Luis Borges | M | 62 | 5 anni | |
Michael Loberg | M | 76 | 8 anni | |
Julie Cherrington | M | 66 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 3 anni |
Robert Steven Sikorski | M | - | 3 anni | |
Alejandro Dorenbaum | M | 64 |
The University of California, San Francisco
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 8 anni |
Anna L. Barry | M | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 8 anni |
Lindsey Rolfe | M | 56 | 13 anni | |
Ryan Watts | M | 48 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 11 anni |
Asha Das | M | 59 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 7 anni |
Jeffrey Schwartz | M | 45 | 6 anni | |
Ingrid Boyes | F | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 10 anni |
Daniel S. Chen | M | 55 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 15 anni |
L. Smith | M | 57 | 7 anni | |
Alexander Hardy | M | 56 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
John M. Whiting | M | 69 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 20 anni |
Sandra Horning | M | 75 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
Steven Hoerter | M | 53 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 11 anni |
Kevin P. Baker | M | 63 | 12 anni | |
Kapil Dhingra | M | 64 | 6 anni | |
Douglas Manion | M | 64 | 11 anni | |
Marc Tessier-Lavigne | M | 64 |
The University of California, San Francisco
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 19 anni |
Markus Gemuend | M | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
Brian Daniels | M | 65 | - | |
Bihua Chen | F | 55 | - | |
Myrtle Potter | F | 65 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 5 anni |
Stephen G. Juelsgaard | M | 75 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 24 anni |
Laurie Glimcher | M | 72 | 20 anni | |
Jeffrey Jones | M | 53 | 5 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 97 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Julie Hambleton
- Contatti personali